Thyroxin in Subclinical Hypothyroidism

Hawler Medical University168 enrolled

Overview

Subclinical hypothyroidism(SCH) is the elevated thyroid stimulating hormone (TSH) with normal free Thyroxine levels and it is a mild or compensated form of primary hypothyroidism. It has been suggested that SCH is more prevalent in infertile women (especially in women with ovulatory disorders.Various rates of SCH was reported in infertile women in different populations

Despite well-established recommendations on screening and treatment of overt hypothyroid in infertile women, there is a controversy regard the treatment of SCH in infertile women . There are few published data on the prevalence of SCH and the outcome of treatment of SCH in infertile women, many were conducted during IVF cycles . Moreover there are inconsistent results in these studies being authors advised to treat SCH before IVF and some other articles find out no any benefit regarding treatment with Thyroxine in SCH

Study Type

INTERVENTIONAL

Allocation

Purpose

SCREENING

Masking

NONE

Enrollment

168

Conditions

Sub Clinical Hypothyroidism Pregnancy Loss

Interventions

ThyroxineDRUG

Thyroxine was prescribed with the diagnosis of SCH and continued when pregnancy was confirmed

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 42 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Unexplained infertility 2. TSH more than 2.5 and normal T3,T4 levels 3. Negative for Anti-thyroid antibodies Exclusion Criteria: 1. current history of overt hypo or hyperthyroidism 2. recurrent pregnancy loss 3. women having franked causes for infertility like tubal blockage, pelvic inflammatory disease, endometriosis , ,uterine factor 4. Ovarian dysfunction or decreased ovarian reserve 5. abnormal seminal fluid analysis or male factor

Outcomes

Primary Outcomes

Pregnancy

Pregnancy was confirmed using human chorionic gonadotropin hormone (hCG) estimation from blood

Time frame: 2 years

Secondary Outcomes

Miscarriage rate

viability and growth of embryos were confirmed by ultrasound

Time frame: 13 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.